Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials

Background Metronomic chemotherapy (‘less is more, regularly’) could be an alternative to the maximum tolerated dose (‘the more, the better’) in the chemotherapeutic cancer treatment of high-risk malignant solid extracranial tumours in children or young adults.Objective To evaluate the efficacy of m...

Full description

Saved in:
Bibliographic Details
Main Authors: Frank Peinemann, Marc Hoemberg
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/10/e084477.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850198648123555840
author Frank Peinemann
Marc Hoemberg
author_facet Frank Peinemann
Marc Hoemberg
author_sort Frank Peinemann
collection DOAJ
description Background Metronomic chemotherapy (‘less is more, regularly’) could be an alternative to the maximum tolerated dose (‘the more, the better’) in the chemotherapeutic cancer treatment of high-risk malignant solid extracranial tumours in children or young adults.Objective To evaluate the efficacy of metronomic chemotherapy compared with placebo or stop treatment in paediatric patients with extracranial malignant solid tumours.Methods We searched the databases MEDLINE and CENTRAL on 8 September 2023 and included randomised clinical trials (RCTs). Primary outcome was overall survival, and the main outcome measure was the HR.Results We identified three RCTs with parallel assignment and intention-to-treat analyses of data from 775 people. The studies primarily reported on participants with rhabdomyosarcoma, neuroblastoma and osteosarcoma. The HR favoured the metronomic chemotherapy group (0.75 (95% CI 0.56 to 0.98)).Conclusions The evidence base is compatible with a favourable effect of metronomic chemotherapy on children and young adults with high-risk extracranial malignant solid tumours, especially other than bone tumours, when compared with placebo or stop treatment. Statistical heterogeneity is low while clinical heterogeneity is substantial. Thus, the results must be interpreted with caution and applicability of the results is limited. Future RCTs could provide more data on individual tumour entities and subsequently add information on tumour-specific responses.PROSPERO registration number CRD42023457195.
format Article
id doaj-art-63df240f8bc243629b55fc9d4dcc7597
institution OA Journals
issn 2044-6055
language English
publishDate 2024-10-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-63df240f8bc243629b55fc9d4dcc75972025-08-20T02:12:49ZengBMJ Publishing GroupBMJ Open2044-60552024-10-01141010.1136/bmjopen-2024-084477Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trialsFrank Peinemann0Marc Hoemberg1Children`s Hospital, University of Cologne, Cologne, GermanyChildren`s Hospital, University of Cologne, Cologne, GermanyBackground Metronomic chemotherapy (‘less is more, regularly’) could be an alternative to the maximum tolerated dose (‘the more, the better’) in the chemotherapeutic cancer treatment of high-risk malignant solid extracranial tumours in children or young adults.Objective To evaluate the efficacy of metronomic chemotherapy compared with placebo or stop treatment in paediatric patients with extracranial malignant solid tumours.Methods We searched the databases MEDLINE and CENTRAL on 8 September 2023 and included randomised clinical trials (RCTs). Primary outcome was overall survival, and the main outcome measure was the HR.Results We identified three RCTs with parallel assignment and intention-to-treat analyses of data from 775 people. The studies primarily reported on participants with rhabdomyosarcoma, neuroblastoma and osteosarcoma. The HR favoured the metronomic chemotherapy group (0.75 (95% CI 0.56 to 0.98)).Conclusions The evidence base is compatible with a favourable effect of metronomic chemotherapy on children and young adults with high-risk extracranial malignant solid tumours, especially other than bone tumours, when compared with placebo or stop treatment. Statistical heterogeneity is low while clinical heterogeneity is substantial. Thus, the results must be interpreted with caution and applicability of the results is limited. Future RCTs could provide more data on individual tumour entities and subsequently add information on tumour-specific responses.PROSPERO registration number CRD42023457195.https://bmjopen.bmj.com/content/14/10/e084477.full
spellingShingle Frank Peinemann
Marc Hoemberg
Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials
BMJ Open
title Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials
title_full Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials
title_fullStr Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials
title_full_unstemmed Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials
title_short Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials
title_sort metronomic chemotherapy for paediatric extracranial solid tumours a systematic review and meta analysis of randomised clinical trials
url https://bmjopen.bmj.com/content/14/10/e084477.full
work_keys_str_mv AT frankpeinemann metronomicchemotherapyforpaediatricextracranialsolidtumoursasystematicreviewandmetaanalysisofrandomisedclinicaltrials
AT marchoemberg metronomicchemotherapyforpaediatricextracranialsolidtumoursasystematicreviewandmetaanalysisofrandomisedclinicaltrials